Catalent (NYSE:CTLT) Announces Earnings Results

Catalent (NYSE:CTLT) posted its quarterly earnings data on Tuesday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18), Briefing.com reports. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the business earned ($0.10) EPS.

Catalent Trading Up 2.5 %

CTLT stock traded up $1.48 during midday trading on Wednesday, reaching $59.96. The company’s stock had a trading volume of 3,536,560 shares, compared to its average volume of 2,046,123. The stock has a fifty day simple moving average of $60.03 and a two-hundred day simple moving average of $58.02. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The firm has a market capitalization of $10.88 billion, a price-to-earnings ratio of -10.65, a PEG ratio of 2.06 and a beta of 1.16. Catalent has a 1 year low of $32.38 and a 1 year high of $61.20.

Insider Buying and Selling

In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.31% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CTLT. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. Robert W. Baird reiterated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, StockNews.com began coverage on shares of Catalent in a research note on Saturday, October 12th. They set a “hold” rating for the company. Nine research analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.